首个BRCA突变早期乳腺癌辅助治疗!阿斯利康“奥拉帕利”新适应症获批

医药魔方Info
02 Jan

1月2日,国家药监局(NMPA)官网显示,阿斯利康的奥拉帕利(olaparib)获批新适应症。根据阿斯利康2024Q3季度报,此次获批的适应症为辅助治疗已在术前或术后接受过化疗治疗的携带BRCA生殖系突变(gBRCAm)的HER2阴性高危早期乳腺癌患者。这是首款也是唯一一款获得批准治疗BRCA突变早期乳腺癌患者的疗法。NMPA此次批准主要是基于III期OlympiA研究的积极数据。该研究纳入了...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10